title: Ay allele promotes azoxymethane-induced colorectal carcinogenesis by macrophage migration in hyperlipidemic/diabetic KK mice.
abstract: The incidence of colorectal cancer has been increasing and is associated with obesity and diabetes. We have found that type 2 diabetes model KK-Ay/TaJcl (KK-Ay) mice develop tumors within a short period after treatment with azoxymethane (AOM). However, factors that contribute to the promotion of carcinogenesis have not been clarified. Therefore, we looked at the genetic background of KK-Ay, including two genetic characteristics of KK/TaJcl (KK) mice and C57BL/6J-Ham-Ay/+ (Ay) mice, compared with other non-obese and non-diabetic mouse strains C57BL/6J and ICR, and induced colorectal premalignant lesions, aberrant crypt foci (ACF), and tumors using AOM (150 μg/mouse/week for 4 weeks and 200 μg/mouse/week for 6 weeks, respectively). The mice with a diabetes feature, KK-Ay and KK, developed significantly more ACF, 67 and 61 per mouse, respectively, whereas ICR, Ay, and C57BL/6J mice developed 42, 24, and 18 ACF/mouse, respectively, at 17 weeks of age. Serum insulin and triglyceride levels in KK-Ay and KK mice were quite high compared with other non-diabetic mouse strains. Interestingly, KK-Ay mice developed more colorectal tumors (2.7 ± 2.3 tumor/mouse) than KK mice (1.2 ± 1.1 tumor/mouse) at 25 weeks of age, in spite of similar diabetic conditions. The colon cancers that developed in both KK-Ay and KK mice showed similar activation of β-catenin signaling. However, mRNA levels of inflammatory factors related to the activation of macrophages were significantly higher in colorectal cancer of KK-Ay mice than in KK. These data indicate that factors such as insulin resistance and dyslipidemia observed in obese and diabetic patients could be involved in susceptibility to colorectal carcinogenesis. In addition, increase of tumor-associated macrophages may play important roles in the stages of promotion of colorectal cancer.
authors.affiliation: Division of Cancer Prevention Research, National Cancer Center Research Institute, Tokyo, Japan.
authors.forename: Kumiko
authors.initials: K
authors.lastname: Ito
authors.forename: Rikako
authors.initials: R
authors.lastname: Ishigamori
authors.forename: Michihiro
authors.initials: M
authors.lastname: Mutoh
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Ohta
authors.forename: Toshio
authors.initials: T
authors.lastname: Imai
authors.forename: Mami
authors.initials: M
authors.lastname: Takahashi
mesh_terms: D000483:Alleles; D000818:Animals; D001397:Azoxymethane; D063646:Carcinogenesis / Q000139:chemically induced / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D002465:Cell Movement / Q000187:drug effects / Q000235:genetics*; D003043:Cocarcinogenesis; D015179:Colorectal Neoplasms / Q000209:etiology* / Q000473:pathology; D003924:Diabetes Mellitus, Type 2 / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D004195:Disease Models, Animal; D005260:Female; D006949:Hyperlipidemias / Q000235:genetics / Q000378:metabolism / Q000473:pathology*; D007249:Inflammation / Q000235:genetics / Q000378:metabolism / Q000473:pathology; D007328:Insulin / Q000097:blood; D008264:Macrophages / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008813:Mice, Inbred ICR; D016688:Mice, Inbred NOD; D012333:RNA, Messenger / Q000235:genetics; D014280:Triglycerides / Q000097:blood; D051176:beta Catenin / Q000235:genetics / Q000378:metabolism
chemical_list: D007328:Insulin; D012333:RNA, Messenger; D014280:Triglycerides; D051176:beta Catenin; D001397:Azoxymethane
references.citation: Horm Cancer. 2010 Dec;1(6):320-30
references.pmid: 21761363
references.citation: Cancer Sci. 2004 Jun;95(6):475-80
references.pmid: 15182426
references.citation: IARC Sci Publ (1971). 1973;(5):119-40
references.pmid: 4377995
references.citation: Endocrinology. 2006 Apr;147(4):1830-7
references.pmid: 16410309
references.citation: Gastroenterology. 2001 Sep;121(3):599-611
references.pmid: 11522744
references.citation: Oncogene. 2009 Nov 5;28(44):3892-902
references.pmid: 19701245
references.citation: Cancer Causes Control. 2005 Sep;16(7):839-50
references.pmid: 16132794
references.citation: Exp Oncol. 2005 Sep;27(3):166-78
references.pmid: 16244576
references.citation: PLoS One. 2010 Jul 22;5(7):e11700
references.pmid: 20661477
references.citation: Carcinogenesis. 2012 Mar;33(3):702-7
references.pmid: 22223845
references.citation: Clin Cancer Res. 2013 Feb 15;19(4):785-97
references.pmid: 23251004
references.citation: Cancer Res. 2003 Feb 1;63(3):728-34
references.pmid: 12566320
references.citation: Diabetologia. 1967 Apr;3(2):212-21
references.pmid: 4907141
references.citation: Int J Cancer. 2011 Aug 1;129(3):528-35
references.pmid: 20886595
references.citation: Cancer Res. 2002 Jan 1;62(1):28-32
references.pmid: 11782353
references.citation: Diabetologia. 2003 May;46(5):595-607
references.pmid: 12764580
references.citation: Nutr Cancer. 1997;29(1):69-76
references.pmid: 9383787
references.citation: J Surg Oncol. 2010 Sep 1;102(3):242-8
references.pmid: 20740582
references.citation: Cancer Res. 2007 Feb 1;67(3):1038-45
references.pmid: 17283136
references.citation: Cancer Sci. 2013 Jul;104(7):835-43
references.pmid: 23551905
references.citation: Clin Cancer Res. 2008 Jan 1;14(1):48-54
references.pmid: 18172251
references.citation: Asian Pac J Cancer Prev. 2012;13(8):4067-73
references.pmid: 23098518
references.citation: Am J Med Sci. 2011 Mar;341(3):227-31
references.pmid: 20460980
references.citation: Nature. 1999 Apr 1;398(6726):422-6
references.pmid: 10201372
references.citation: J Biol Chem. 2010 Aug 6;285(32):24665-75
references.pmid: 20519507
references.citation: PLoS One. 2009 Aug 21;4(8):e6713
references.pmid: 19696929
references.citation: Chem Biol Interact. 2005 Jun 30;155(1-2):1-9
references.pmid: 15904905
references.citation: Eur J Cancer Prev. 2009 Jun;18(3):240-7
references.pmid: 19491612